175 related articles for article (PubMed ID: 37993770)
1. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
3. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
4. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.
Russell MD; Roddy E; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Rheumatology (Oxford); 2023 Jul; 62(7):2426-2434. PubMed ID: 36355461
[TBL] [Abstract][Full Text] [Related]
5. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Hu S; Sun M; Li M; Xue X; Terkeltaub R; Wang C; Wang M; Lu J; Ran Z; Li H; Ji A; Sun W; Li X; He Y; Liu Z; Zhang H; Wang X; Ji X; Dalbeth N; Li C
Rheumatology (Oxford); 2023 Jul; 62(7):2435-2443. PubMed ID: 36409036
[TBL] [Abstract][Full Text] [Related]
8. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom.
Russell MD; Rutherford AI; Ellis B; Norton S; Douiri A; Gulliford MC; Cope AP; Galloway JB
Lancet Reg Health Eur; 2022 Jul; 18():100416. PubMed ID: 35814340
[TBL] [Abstract][Full Text] [Related]
9. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
10. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
11. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
12. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Terkeltaub R
Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
[TBL] [Abstract][Full Text] [Related]
13. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Roughley M; Sultan AA; Clarson L; Muller S; Whittle R; Belcher J; Mallen CD; Roddy E
Arthritis Res Ther; 2018 Oct; 20(1):243. PubMed ID: 30376864
[TBL] [Abstract][Full Text] [Related]
14. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
15. [Gout management: an update].
Ankli B; Krähenbühl S
Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
[TBL] [Abstract][Full Text] [Related]
16. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
[TBL] [Abstract][Full Text] [Related]
17. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
[TBL] [Abstract][Full Text] [Related]
18. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
Zhang X; Tang Y; Wang M; Wang D; Li Q
Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
[TBL] [Abstract][Full Text] [Related]
20. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
